Endo International’s subsidiary, Par Sterile Products, LLC has entered into a non-exclusive agreement with Novavax, Inc. to provide fill-finish manufacturing services at its plant in Rochester, MI for Novavax’ COVID-19 vaccine candidate, NVX-CoV2373. Par Sterile’s Rochester facility has begun production of NVX-CoV2373 final drug product, with initial batches to be used in Novavax’ pivotal Phase III trial in the U.S. Par Sterile will also fill-finish NVX-CoV2373 vaccine inte...